Interaction of Apelin and Angiotensin in the Systemic Circulation
1 other identifier
interventional
12
1 country
1
Brief Summary
The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease. Apelin improves that pumping ability of the heart and we wish to know if this action persists in the presence of increased levels of angiotensin II.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2010
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2010
CompletedFirst Submitted
Initial submission to the registry
January 13, 2010
CompletedFirst Posted
Study publicly available on registry
January 14, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2010
CompletedAugust 10, 2010
August 1, 2010
3 months
January 13, 2010
August 9, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cardiac output
90 mins
Secondary Outcomes (1)
Systemic haemodynamics
90mins
Study Arms (2)
Angiotensin II
ACTIVE COMPARATORSaline infusion
PLACEBO COMPARATORInterventions
Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
Eligibility Criteria
You may qualify if:
- \> 18 years old
- Healthy volunteers
You may not qualify if:
- Lack of informed consent
- Age \< 18 years,
- Current involvement in other research studies,
- Systolic blood pressure \>190 mmHg or \<100 mmHg
- Malignant arrhythmias
- Renal or hepatic failure
- Haemodynamically significant aortic stenosis
- Severe or significant co morbidity
- Women of childbearing potential.
- Any regular medication
- Previous history of any cardiovascular disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc
Edinburgh, EH16 4SA, United Kingdom
Related Publications (1)
Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, Veitch S, Jeong H, White A, Cruden NL, Huson L, Japp AG, Newby DE. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail. 2013 May;6(3):482-91. doi: 10.1161/CIRCHEARTFAILURE.111.000077. Epub 2013 Mar 21.
PMID: 23519586DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
January 13, 2010
First Posted
January 14, 2010
Study Start
January 1, 2010
Primary Completion
April 1, 2010
Study Completion
April 1, 2010
Last Updated
August 10, 2010
Record last verified: 2010-08